Partnering for Cures // Expert Consultations

Structuring Deals & Collaborations

These consultations will address various methods for formalizing and carrying out cross-sector partnerships as efficiently and effectively as possible. They will cover issues such as intellectual property, data sharing, and conflicts of interest to ensure that the proper legal and structural agreements/policies/processes are in place for successful collaborations.

Carol Greve-Philips - Former Vice President, Corporate Development, Genzyme Corp.
Carol Greve-Philips is an experienced biotechnology professional with strong business development skills, a varied deal sheet, and a focus on rare and neurodegenerative diseases. In her last role, Greve-Philips was vice president of corporate development at Genzyme Corporation, where she led two transformational transactions for the flagship Personalized Genetic Health business unit. She is a dynamic, strategic, and talented individual who is widely considered to be a leader with deep industry experience, broad business development, and commercial knowledge. Greve-Philips has a strong network of investment bankers, venture capital partners, and industry colleagues who continue to bring novel therapies for her consideration. In addition to her role in corporate development, Greve-Philips was the business unit representative to Genzyme's Translational Biology Steering Committee, where she brought the commercial perspective to the company's pipeline of early stage discovery programs. Prior to joining Genzyme, Greve-Philips worked for a number of contract manufacturing and research organizations, which provided her with a deep understanding of the drug development process from discovery through approval to commercial launch. Greve-Philips has a bachelor's degree from the University of Massachusetts at Amherst. She is best known for her ability to develop and maintain highly productive teams and collaborations.

David Lubitz - Partner, Schaner & Lubitz, PLLC
David Lubitz is a partner in Schaner & Lubitz, LLP, www.schanerlaw.com, a law firm that specializes in providing outside general counsel services to disease foundations and helping them invest in scientific innovation leading to cures and therapies. Lubitz has been practicing law for 20 years. He serves as counsel to or has advised: the Cystic Fibrosis Foundation and its affiliates, American Clean Skies Foundation, Global Impact, The Michael J. Fox Foundation for Parkinson's Research, National Childhood Cancer Foundation, Juvenile Diabetes Research Foundation, Multiple Myeloma Research Foundation, Simons Foundation, National Neurovision Research Institute, Cancer Research Institute, CNS Regenerative Medicine Foundation, and other 501(c)(3) tax exempt organizations. Lubitz was a law partner at two firms in Washington, D.C., Swidler Berlin and Bingham McCutchen, before forming Schaner & Lubitz. He is a graduate of the Columbia Law School and Harvard College.

John McKew - Chief, Therapeutic Development Branch, National Center for Translational Therapeutics, National Institutes of Health
John McKew is chief of the Therapeutic Development Branch at the National Center for Translational Therapeutics (NCTT) at the National Institutes of Health (NIH) and the director of chemistry for the NCTT. Within the branch are the Therapeutics for Rare and Neglected Diseases program and the Bridging Interventional Development Gaps program. The branch is focused on building an intramural research group tasked with soliciting and advancing projects through discovery and preclinical development. Prior to joining the NIH, McKew held a director-level position at Wyeth Research and began his career at the Genetics Institute in Cambridge, Mass. where he spent 17 years. At Wyeth, he led a hit-to-lead chemistry group dedicated to the cardiovascular, musculoskeletal, and metabolic diseases therapeutic areas. Prior to that, McKew spent 10 years working in the inflammation therapeutic area resulting in multiple compounds entering clinical evaluation. McKew graduated from State University of New York at Stony Brook with degrees in chemistry and biochemistry. He completed his doctorate in organic chemistry at University of California. He is the immediate past chair of the Northeastern Section of the American Chemical Society and an adjunct associate professor at Boston University School of Medicine, Department of Pharmacology and Experimental Therapeutics.

Teri Melese - Associate Professor and Director of Research Technologies and Alliances, University of California, San Francisco School of Medicine
Teri Melese is an associate professor in the department of medicine at the University of California, San Francisco (UCSF) and is the director of research technologies and alliances in the UCSF School of Medicine Dean's Office. In this position she works with institute and center directors, as well as individual faculty, and life science companies to craft and implement research collaborations. She is on the executive leadership team of the Helen Diller Family Comprehensive Cancer Center. Melese has published a number of articles in high-impact journals on the nature of effective academic/industry partnerships. Before joining UCSF in 2001, she ran an independent research laboratory in yeast genetics and molecular biology at Columbia University from 1988 to 1997, where she was awarded a National Science Foundation Young Presidential Investigator Award. In 1997 she left Columbia to be founding member of a venture-backed start up company, Iconix Biosciences (acquired by Entelos), in Silicon Valley. She has four patents for biomedical technologies and small molecule inhibitors. Melese holds a bachelor of arts from the University of California, Berkeley, a doctorate in cell biology from UCSF (Regents Fellow), and was an American Cancer Senior Postdoctoral Fellow at the University of California, Los Angeles.

Eric Nelson - Chief Executive Officer, NCE Biotech Consulting
Eric Nelson is a pharmaceutical industry business development and drug program management consultant. His focus areas are rare disease drug programs and disease foundation strategies; pharmaceutical and biotechnology collaborations and partnership agreements; drug development CRO contracting and preferred vendors; technology transfer and data sharing contractual agreements; public-private partnerships formation and funding; NIH drug development programs and funding; and natural history studies, biomarkers, FDA review, and patient registries. Currently he works with the University of Alabama at Birmingham rheumatoid arthritis biomarker program, with ParentProject Muscular Dystrophy, and is affiliated with the law firm of Schaner & Lubitz. During 2010-11 he was consultant to the National Institutes of Health (NIH) Therapeutics for Rare & Neglected Diseases (TRND) program. He has worked for many clients, including for Kleiner Perkins, SROne, 3D Pharmaceuticals, Geron, Santhera, Celldex, Glycart, the University of Pennsylvania, and the Foundation for the NIH Biomarker Consortium. He has been a head of business development at Athena Neurosciences, Becton Dickinson, and Wyeth Pharmaceuticals. He has completed 30 partnership agreements worth more than $1 billion. He received his doctorate in molecular biology at Johns Hopkins School of Medicine and was a post-doctoral fellow at Harvard's Department of Biochemistry.

Mark Scheideler - Founder, Human First Therapeutics LLC
Mark Scheideler founded HumanFirst Therapeutics LLC to provide consulting and management to translational research initiatives. The company mission is to accelerate therapeutics development by forming partnerships to validate disease targets, biomarkers, and drug treatment strategies. Utilizing a network approach that partners academic-medical disease area experts, disease foundations, drug developers, and government, HumanFirst Therapeutics facilitates the formation and operational implementation of therapy development partnerships. As a senior scientific officer at the National Institutes of Health (NIH) from 2005 to 2011, Scheideler worked with translational research initiatives spanning the 27 institutes and centers. He came to the NIH with 14 years of international pharmaceutical and biotechnology research & development experience in Europe and North America. Key assignments included posts as managing director-Europe and senior vice president at MDS-Proteomics, head of neurobiology research at SmithKline Beecham (and GlaxoSmithKline), and principal scientist & program head at Novo Nordisk Healthcare. Scheideler previously held academic posts as research assistant professor at Albert Einstein College of Medicine and research fellow at Duke University Medical Center. He holds a doctorate in biochemistry from the University of Chicago, a bachelor of arts in biochemistry & molecular biology from Northwestern University, and certificate in finance & accounting from the Wharton School of Business.

DISCLAIMER
The Expert Consultations at Partnering for Cures are informal sessions intended to be informational in nature. The individuals serving in the role of experts are providing their advice pro bono, and before acting upon any such advice you should consult with your own experts or consultants who are more familiar with your particular organizations. Neither the consultants nor the sponsors of Partnering for Cures shall be liable in any manner with respect to the outcomes or consequences that may result from any actions taken based upon the guidance offered in these sessions.

2011
Sponsors